TBH many bio techs de/prioritise their works, Another company comes to mind that recently did the same....But I suppose that's the whole point of not being a one trick pony. Her-vaxx completed phase 2 with favourable results, yes it's not going to take-over Herceptin but it didn't fail. Phase 3 simply cost too much, so unless there is a buyer, there is no need/ability to continue. Neo-Polem has now been updated from Not recruiting to a recruiting, so that arm isn't shelved. But you're right about the 90% decline and there's no arguing that. I don't think it's all about Hervaxx. Our SOI has played a huge factor, we can't hold a green for more than 2 days even with positive news. Not to cross talk, but RAC jumped 25% on news of the ethics approval, which was always going to come through, they maintained that gain for the most part although it's drifted a bit lower since. IMU announce multiple CRs which is highly significant for any drug and then it gets smashed right back down to levels lower than the time the announcement was made. That is more than a Her-Vaxx related issue.
IMU Price at posting:
3.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)